SCHEMBL20645261

SCHEMBL20645261

CN(C)c1ccc(-c2ncc(Br)s2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 1/20 0.51
GAA P10253 3/20 0.49
MGAM O43451 1/20 0.49
SI P14410 1/20 0.49
MGAM2 Q2M2H8 1/20 0.49
APP P05067 10/20 0.48
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 2/20 0.47
GLA P06280 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
KDM4E B2RXH2 1/20 0.47
TP53 P04637 1/20 0.47
HPGD P15428 1/20 0.47
HDAC1 Q13547 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.42
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26759054 0.76 GAA (0.46) GAAMGAMSIMGAM2APP
SCHEMBL20641452 0.76 LMNA (0.46) SNCAMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL22466129 0.76 SNCA (0.56) SNCAGAAMGAMSIMGAM2
SCHEMBL14157145 0.76 SNCA (0.66) SNCAGAAMGAMSIMGAM2
SCHEMBL15090524 0.76 SNCA (0.56) SNCAMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL25382795 0.76 SNCA (0.56) SNCAAPPMAPTSMN1; SMN2ALDH1A1
SCHEMBL20641446 0.76 SNCA (0.56) SNCAGAAAPPMAPTSMN1; SMN2
SCHEMBL1181322 0.75 SNCA (0.51) SNCAAPPMAPTSMN1; SMN2ALDH1A1
SCHEMBL928439 0.75 SNCA (0.55) SNCAMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL1849553 0.75 GAA (0.45) GAAMGAMSIMGAM2APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3652159-B1 SUBSTITUTED THIAZOLE DERIVATIVES AS RAD51 INHIBITORS FOR THE TREATMENT OF CANCER DISEASES, AUTOIMMUNE AND NEURODEGENERATIVE CONDITIONS CYTEIR THERAPEUTICS INC (US) 2023-01-18 EP disclosed
WO-2019014315-A1 RAD51 INHIBITORS CYTEIR THERAPEUTICS, INC. (US) 2019-01-17 WO disclosed